Analyst Price Target is $9.00
▲ +85.19% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Genfit in the last 3 months. The average price target is $9.00, with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 85.19% upside from the last price of $4.86.
Current Consensus is
The current consensus among 3 polled investment analysts is to buy stock in Genfit. This Buy consensus rating has held steady for over two years.
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.